Brain Cancer Diagnostics Market

Brain Cancer Diagnostics Market (Diagnostic Technique: Imaging Techniques, Tissue Sampling/Biopsy, Molecular Diagnostics, and Others; Brain Cancer Type: Gliomas, Meningiomas, Pituitary Tumors, and others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Brain Cancer Diagnostics Market Outlook 2023

  • The global industry was valued at US$ 1.5 Bn in 2022
  • It is projected to grow at a CAGR of 5.9% from 2023 to 2031 and reach more than US$ 2.5 Bn by the end of 2031

Analyst Viewpoint

Surge in prevalence of neurological disorders & cancer owing to rise in number of individuals who smoke is driving the global brain cancer diagnostics industry. This escalating health concern necessitates the development and adoption of advanced diagnostic solutions to effectively address these challenges. Rise in awareness and increase in screening programs for brain cancer are the other factors propelling market expansion. Furthermore, technological advancements in non-invasive techniques are expected to bolster the global brain cancer diagnostics market size during the forecast period.

Development of more advanced, accurate, and efficient diagnostic technique offers lucrative opportunities to market players. Companies are focusing on development of non-invasive diagnostic tools that offer rapid and secure means to visualize the brain's internal structures.

Brain Cancer Diagnostics Market

Global Brain Cancer Diagnostics Market Introduction

Brain cancer diagnostics include a comprehensive array of medical procedures and tests designed to identify and assess the presence of brain tumors and other abnormalities within the brain. This diagnostic process is of paramount importance as it serves as the foundation for informed treatment decisions and ultimately influences patient outcomes.

Non-invasive techniques play a pivotal role in modern medicine, offering alternatives to invasive procedures such as brain biopsy. These techniques encompass both physical inspections of the body and advanced imaging modalities, particularly when it comes to the examination of the brain.

Computed tomography (CT) scans and magnetic resonance imaging (MRI) are the most widely used non-invasive imaging methods for brain cancer. These techniques provide rapid and secure means to visualize the brain's internal structures, enabling radiologists and healthcare professionals to identify various brain problems, track the progression of diseases, and plan surgical interventions.

Detecting and segmenting brain tumors is one of the most complex and critical tasks in medical imaging. Brain tumors are of diverse shapes and sizes, making it a challenging endeavor that often necessitates a substantial amount of data and information.

Surge in Prevalence of Brain Tumors and Rise in Awareness & Increase in Screening Programs

The global brain cancer diagnostics market demand has experienced robust growth in the past few years. This is ascribed to surge in prevalence of brain tumors, particularly malignant glioblastoma, and rise in awareness about early detection facilitated by government-backed screening programs.

Incidence of brain tumors is increasing as the global population continues to age. Moreover, persisting risk factors, such as smoking and environmental exposure, contribute to increase in demand for accurate diagnostic tools.

Glioblastoma, a particularly malignant form of brain tumor, exemplifies the urgency of early detection. This fast-growing and lethal condition underscores the critical need for swift diagnosis and intervention to enhance patient outcomes.

Increase in awareness about the importance of early detection and implementation of government-backed screening programs plays a pivotal role in bolstering global brain cancer diagnostics market growth.

Public awareness campaigns have shed light on the significance of identifying brain tumors at an early, more treatable stages. These initiatives encourage individuals to proactively seek regular check-ups and screenings, not only enhancing the chances of early diagnosis, but also promoting general health consciousness.

Increase in awareness has enabled more individuals to take proactive steps to include brain cancer diagnostics in their healthcare routines. This not only benefits individual patients but also leads to broader public health benefits by reducing the overall burden of advanced-stage brain cancers on healthcare systems.

Around 12,288 new cases of brain and CNS tumors are diagnosed in the U.K. each year, with brain tumor ranking as the ninth most common malignancy, accounting for 3% of all new cancer cases. Similar trends are observed in Australia, where thousands of new brain cancer cases are reported annually.

Technological Advancements in Non-invasive Techniques Driving Market Progress

Technological advancements in non-invasive diagnostic techniques is driving the global brain cancer diagnostics industry. These innovations not only contribute to the ongoing demand for brain cancer diagnostics, but also hold great promise for the future of healthcare.

Development of noninvasive diagnostic techniques is a major factor bolstering the global brain cancer diagnostics market value. These techniques offer a patient-friendly approach that reduces the need for invasive procedures such as biopsies.

Non-invasive methods not only minimize patient discomfort, but also enhance safety, early detection, and diagnostic accuracy. These are becoming increasingly important in improving the patient experience and encouraging more individuals to undergo regular brain cancer screenings. Moreover, non-invasive techniques are instrumental in detecting tumors in the early, more treatable stages, leading to better patient outcomes.

Increase in Reliance on Imaging Technologies in Brain Tumor Detection

In terms of diagnostic technique, the imaging techniques segment dominated the global brain cancer diagnostics market. This is ascribed to increase in reliance on imaging technologies in the diagnosis of a brain cancer. Magnetic Resonance Imaging (MRI) is a major medical imaging technique in radiology, contributing to the production of detailed anatomical images and insights into the body's physiological processes.

Rise in prevalence of brain cancer cases is also expected to propel demand for brain tumor diagnostics during the forecast period. In February 2023, Case Western Reserve University received a substantial grant of US$ 3 Mn to advance novel MRI technology and software specifically designed for brain tumor diagnosis. This development holds significant promise as it has the potential to revolutionize the field of brain cancer diagnostics.

Utilization of advanced MRI technology, along with specialized software, can provide highly detailed images and data that are essential for personalized treatment planning. This, in turn, can significantly improve patient outcomes by enabling healthcare providers to tailor treatments to the unique characteristics of each patient's brain tumor.

Integration of cutting-edge MRI technology and software advancements exemplifies the commitment of the healthcare and research community to continuously enhance the capabilities of diagnostic tools for brain cancer. This effort not only underscores the importance of MRI but also highlights the potential for innovative technologies to contribute to improved patient care.

Rise in Prevalence and Diverse Nature of Gliomas

Based on brain cancer type, the gliomas segment is expected to account for the largest global brain cancer diagnostics market share during the forecast period. This is ascribed to wide spectrum of subtypes of gliomas and their impact on brain health. Gliomas are characterized by their highly infiltrative nature, which affects the surrounding brain tissue, making their accurate diagnosis and monitoring crucial.

Glioblastoma is the most malignant subtype of glioma. This aggressive form of brain cancer grows rapidly and is associated with a poor prognosis, emphasizing the urgency of early and precise diagnosis.

High prevalence and diverse nature of gliomas necessitate advanced and specialized diagnostic approaches for accurate characterization and tailored treatment planning. The global brain cancer diagnostics market, therefore, continues to place strong emphasis on glioma diagnostics, given their clinical significance and their impact on the lives of patients.

This underscores the importance of ongoing research, technological advancements, and multidisciplinary collaboration in the field of brain cancer diagnostics to address the challenges posed by gliomas effectively.

Availability of State-of-the-Art Equipment in Hospitals

In terms of end-user, the hospitals segment is likely to dominate the global brain cancer diagnostics market during the forecast period. Hospitals play a pivotal role in accurate and early diagnosis of brain cancer.

The healthcare landscape, characterized by increase in prevalence of brain tumors and the critical need for timely and precise diagnostics, places hospitals at the forefront of this essential endeavor.

Hospitals have state-of-the-art equipment, including MRI, CT, PET, various specialized imaging technologies; and a diverse team of healthcare professionals, such as radiologists, neurosurgeons, oncologists, and pathologists.

These facilities are crucial for providing detailed scans and expert interpretation, making them a primary destination for patients seeking accurate brain cancer assessment. This multidisciplinary approach ensures a comprehensive evaluation of brain cancer cases, allowing for individualized and accurate diagnoses.

Regional Outlook

According to brain cancer diagnostics market analysis, North America dominated the global industry in 2022. This is ascribed to increase in incidence of brain cancer cases across the region. High prevalence of brain cancer necessitates advanced diagnostic tools to improve early detection and treatment outcomes.

Ongoing clinical trials conducted by multiple companies in North America also contribute to market expansion. These trials aim to develop more effective treatments, emphasizing the importance of early and accurate diagnosis as the first step in the management of brain cancer.

Aa per brain cancer diagnostics market forecast, the industry in Asia Pacific is driven by rise in incidence of brain cancer, improved diagnostic technologies, and growing awareness about early cerebral tumor detection. Moreover, presence of key players such as GE Healthcare and Siemens Healthineers offering innovative diagnostic solutions is expected to fuel the brain cancer diagnostics industry revenue in Asia Pacific during the forecast period. Furthermore, increase in healthcare investment, rise in research & development activities, and surge in elderly population are driving market growth in the region.

Analysis of Key Players

The global brain cancer diagnostics market is fragmented, with the presence of large number of players. Companies are focusing investing in R&D and merger & acquisition in order to increase market share and presence.

GE Healthcare, Siemens Healthineers, Philips Healthcare, Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, Illumina, Inc., Hologic, Inc., Agilent Technologies, and Bio-Rad Laboratories are the prominent players in the market.

Key Developments in Global Brain Cancer Diagnostics Market

  • In October 2022, Royal Philips announced two new improvements in MR-only workflows to advance head and neck cancer radiotherapy imaging and simulation. The company’s artificial intelligence (AI) enabled MRCAT Head and Neck radiotherapy application, which allows the use of MR as the sole or primary imaging modality for radiotherapy planning in the treatment of soft tissue tumors in the head and neck, along with the brain, pelvis, and prostate, received FDA 510(k) clearance and is commercially available in the U.S.
  • In September 2022, GE Healthcare received the U.S. FDA 510(k) clearance for its breakthrough AIR Recon DL for 3D and PROPELLER imaging sequences. By expanding AIR Recon DL to 3D and PROPELLER, GE Healthcare closed the gaps to provide improved image quality and patient experience to all patients across exam types, particularly for brain imaging.
  • In November 2021, the National Brain Research Centre (NBRC) in India installed a sophisticated MRI Scanner PRISMA 3T MRI from Siemens. This MRI facility is dedicated to neuroscience research and education and signifies the global push toward advanced imaging technologies for brain cancer diagnostics. These state-of-the-art facilities and technologies enhance the precision and speed of diagnostics, further underlining the significance of technological advancements in the field.

Each of these players has been profiled in the brain cancer diagnostics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Brain Cancer Diagnostics Market Snapshot

Attribute Detail
Size in 2022 US$ 1.5 Bn
Forecast (Value) in 2031 More than US$ 2.5 Bn
Growth Rate (CAGR ) 5.9%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Segmentation
  • Diagnostic Technique
    • Imaging Techniques
      • Magnetic Resonance Imaging (MRI),
      • Computed Tomography (CT) Scan
      • PET Scan or PET-CT Scan
      • Single-photon Emission Computed Tomography (SPECT) Scan
    • Tissue Sampling/Biopsy
    • Molecular Diagnostics
    • Others
  • Brain Cancer Type
    • Gliomas
    • Meningiomas
    • Pituitary tumors
    • Others
  • End-user
    • Hospitals
    • Diagnostic Laboratories
    • Cancer Hospitals/Centers
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa
Companies Profiled
  • GE Healthcare
  • Siemens Healthineers
  • Philips Healthcare
  • Thermo Fisher Scientific
  • Roche Diagnostics
  • Abbott Laboratories
  • Illumina, Inc.
  • Hologic, Inc.
  • Agilent Technologies
  • Bio-Rad Laboratories

Frequently Asked Questions

How big was the global brain cancer diagnostics market in 2022?

It was valued at US$ 1.5 Bn in 2022

How big will the brain cancer diagnostics business be in 2031?

It is projected to reach more than US$ 2.5 Bn by 2031

What will the CAGR of the brain cancer diagnostics industry be during the forecast period?

It is anticipated to grow at a CAGR of 5.9% from 2023 to 2031

Which are the prominent trends driving demand for brain cancer diagnostics?

Surge in prevalence of brain tumors and increase in awareness & rise in screening programs

Which region will account for major share of the brain cancer diagnostics sector during the forecast period?

North America is expected to account for largest share during the forecast period.

Who are the prominent brain cancer diagnostics players?

GE Healthcare, Siemens Healthineers, Philips Healthcare, Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, Illumina, Inc., Hologic, Inc., Agilent Technologies, and Bio-Rad Laboratories

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Brain Cancer Diagnostics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Brain Cancer Diagnostics Market Analysis and Forecasts, 2023–2031

5. Key Insights

    5.1. Brain Tumor Epidemiology

    5.2. Current Trends in Diagnostic and Therapeutic Imaging of Brain Tumors

    5.3. Technological advancements in cancer diagnostics

    5.4. COVID-19 Impact Analysis

6. Global Brain Cancer Diagnostics Market Analysis and Forecasts, by Diagnostic Technique

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Diagnostic Technique, 2023–2031

        6.3.1. Imaging Techniques

            6.3.1.1. Magnetic Resonance Imaging (MRI)

            6.3.1.2. Computed Tomography (CT) Scan

            6.3.1.3. PET Scan or PET-CT Scan

            6.3.1.4. (SPECT) Scan

        6.3.2. Tissue Sampling/Biopsy

        6.3.3. Molecular Diagnostics

        6.3.4. Others

    6.4. Market Attractiveness Analysis, by Diagnostic Technique

7. Global Brain Cancer Diagnostics Market Analysis and Forecasts, by Brain Cancer Type

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Brain Cancer Type, 2023–2031

        7.3.1. Gliomas

        7.3.2. Meningiomas

        7.3.3. Pituitary Tumors

        7.3.4. Others

    7.4. Market Attractiveness Analysis, by Brain Cancer Type

8. Global Brain Cancer Diagnostics Market Analysis and Forecasts, by End-user

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by End-user, 2023–2031

        8.3.1. Hospitals

        8.3.2. Diagnostic Laboratories

        8.3.3. Cancer Hospitals/Centers

    8.4. Market Attractiveness Analysis, by End-user

9. Global Brain Cancer Diagnostics Market Analysis and Forecasts, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Brain Cancer Diagnostics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Diagnostic Technique, 2023–2031

        10.2.1. Imaging Techniques

            10.2.1.1. Magnetic Resonance Imaging (MRI)

            10.2.1.2. Computed Tomography (CT) Scan

            10.2.1.3. PET Scan or PET-CT Scan

            10.2.1.4. (SPECT) Scan

        10.2.2. Tissue Sampling/Biopsy

        10.2.3. Molecular Diagnostics

        10.2.4. Others

    10.3. Market Value Forecast, by Brain Cancer Type, 2023–2031

        10.3.1. Gliomas

        10.3.2. Meningiomas

        10.3.3. Pituitary Tumors

        10.3.4. Others

    10.4. Market Value Forecast, by End-user, 2023–2031

        10.4.1. Hospitals

        10.4.2. Diagnostic Laboratories

        10.4.3. Cancer Hospitals/Centers

    10.5. Market Value Forecast, by Country, 2023–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Diagnostic Technique

        10.6.2. By Brain Cancer Type

        10.6.3. By End-user

        10.6.4. By Country

11. Europe Brain Cancer Diagnostics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Diagnostic Technique, 2023–2031

        11.2.1. Imaging Techniques

            11.2.1.1. Magnetic Resonance Imaging (MRI)

            11.2.1.2. Computed Tomography (CT) Scan

            11.2.1.3. PET Scan or PET-CT Scan

            11.2.1.4. (SPECT) Scan

        11.2.2. Tissue Sampling/Biopsy

        11.2.3. Molecular Diagnostics

        11.2.4. Others

    11.3. Market Value Forecast, by Brain Cancer Type, 2023–2031

        11.3.1. Gliomas

        11.3.2. Meningiomas

        11.3.3. Pituitary Tumors

        11.3.4. Others

    11.4. Market Value Forecast, by End-user, 2023–2031

        11.4.1. Hospitals

        11.4.2. Diagnostic Laboratories

        11.4.3. Cancer Hospitals/Centers

    11.5. Market Value Forecast, by Country/Sub-region, 2023–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Italy

        11.5.5. Spain

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Diagnostic Technique

        11.6.2. By Brain Cancer Type

        11.6.3. By End-user

        11.6.4. By Country/Sub-region

12. Asia Pacific Brain Cancer Diagnostics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Diagnostic Technique, 2023–2031

        12.2.1. Imaging Techniques

            12.2.1.1. Magnetic Resonance Imaging (MRI)

            12.2.1.2. Computed Tomography (CT) Scan

            12.2.1.3. PET Scan or PET-CT Scan

            12.2.1.4. (SPECT) Scan

        12.2.2. Tissue Sampling/Biopsy

        12.2.3. Molecular Diagnostics

        12.2.4. Others

    12.3. Market Value Forecast, by Brain Cancer Type, 2023–2031

        12.3.1. Gliomas

        12.3.2. Meningiomas

        12.3.3. Pituitary Tumors

        12.3.4. Others

    12.4. Market Value Forecast, by End-user, 2023–2031

        12.4.1. Hospitals

        12.4.2. Diagnostic Laboratories

        12.4.3. Cancer Hospitals/Centers

    12.5. Market Value Forecast, by Country/Sub-region, 2023–2031

        12.5.1. China

        12.5.2. India

        12.5.3. Japan

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Diagnostic Technique

        12.6.2. By Brain Cancer Type

        12.6.3. By End-user

        12.6.4. By Country/Sub-region

13. Latin America Brain Cancer Diagnostics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Diagnostic Technique, 2023–2031

        13.2.1. Imaging Techniques

            13.2.1.1. Magnetic Resonance Imaging (MRI)

            13.2.1.2. Computed Tomography (CT) Scan

            13.2.1.3. PET Scan or PET-CT Scan

            13.2.1.4. (SPECT) Scan

        13.2.2. Tissue Sampling/Biopsy

        13.2.3. Molecular Diagnostics

        13.2.4. Others

    13.3. Market Value Forecast, by Brain Cancer Type, 2023–2031

        13.3.1. Gliomas

        13.3.2. Meningiomas

        13.3.3. Pituitary Tumors

        13.3.4. Others

    13.4. Market Value Forecast, by End-user, 2023–2031

        13.4.1. Hospitals

        13.4.2. Diagnostic Laboratories

        13.4.3. Cancer Hospitals/Centers

    13.5. Market Value Forecast, by Country/Sub-region, 2023–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Diagnostic Technique

        13.6.2. By Brain Cancer Type

        13.6.3. By End-user

        13.6.4. By Country/Sub-region

14. Middle East & Africa Brain Cancer Diagnostics Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Diagnostic Technique, 2023–2031

        14.2.1. Imaging Techniques

            14.2.1.1. Magnetic Resonance Imaging (MRI)

            14.2.1.2. Computed Tomography (CT) Scan

            14.2.1.3. PET Scan or PET-CT Scan

            14.2.1.4. (SPECT) Scan

        14.2.2. Tissue Sampling/Biopsy

        14.2.3. Molecular Diagnostics

        14.2.4. Others

    14.3. Market Value Forecast, by Brain Cancer Type, 2023–2031

        14.3.1. Gliomas

        14.3.2. Meningiomas

        14.3.3. Pituitary Tumors

        14.3.4. Others

    14.4. Market Value Forecast, by End-user, 2023–2031

        14.4.1. Hospitals

        14.4.2. Diagnostic Laboratories

        14.4.3. Cancer Hospitals/Centers

    14.5. Market Value Forecast, by Country/Sub-region, 2023–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Diagnostic Technique

        14.6.2. By Brain Cancer Type

        14.6.3. By End-user

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player – Competition Matrix (By Tier and Size of companies)

    15.2. Market Share Analysis By Company (2021)

    15.3. Company Profiles

        15.3.1. GE Healthcare

            15.3.1.1. Company Overview

            15.3.1.2. Financial Overview

            15.3.1.3. Product Portfolio

            15.3.1.4. Strategic Overview

            15.3.1.5. SWOT Analysis

        15.3.2. Siemens Healthineers

            15.3.2.1. Company Overview

            15.3.2.2. Financial Overview

            15.3.2.3. Product Portfolio

            15.3.2.4. Strategic Overview

            15.3.2.5. SWOT Analysis

        15.3.3. Philips Healthcare

            15.3.3.1. Company Overview

            15.3.3.2. Financial Overview

            15.3.3.3. Product Portfolio

            15.3.3.4. Strategic Overview

            15.3.3.5. SWOT Analysis

        15.3.4. Thermo Fisher Scientific

            15.3.4.1. Company Overview

            15.3.4.2. Financial Overview

            15.3.4.3. Product Portfolio

            15.3.4.4. Strategic Overview

            15.3.4.5. SWOT Analysis

        15.3.5. Roche Diagnostics

            15.3.5.1. Company Overview

            15.3.5.2. Financial Overview

            15.3.5.3. Product Portfolio

            15.3.5.4. Strategic Overview

            15.3.5.5. SWOT Analysis

        15.3.6. Abbott Laboratories

            15.3.6.1. Company Overview

            15.3.6.2. Financial Overview

            15.3.6.3. Product Portfolio

            15.3.6.4. Strategic Overview

            15.3.6.5. SWOT Analysis

        15.3.7. Illumina, Inc.

            15.3.7.1. Company Overview

            15.3.7.2. Financial Overview

            15.3.7.3. Product Portfolio

            15.3.7.4. Strategic Overview

            15.3.7.5. SWOT Analysis

        15.3.8. Hologic, Inc.

            15.3.8.1. Company Overview

            15.3.8.2. Financial Overview

            15.3.8.3. Product Portfolio

            15.3.8.4. Strategic Overview

            15.3.8.5. SWOT Analysis

        15.3.9. Agilent Technologies

            15.3.9.1. Company Overview

            15.3.9.2. Financial Overview

            15.3.9.3. Product Portfolio

            15.3.9.4. Strategic Overview

            15.3.9.5. SWOT Analysis

        15.3.10. Bio-Rad Laboratories

            15.3.10.1. Company Overview

            15.3.10.2. Financial Overview

            15.3.10.3. Product Portfolio

            15.3.10.4. Strategic Overview

            15.3.10.5. SWOT Analysis

List of Tables

Table 01: Global Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Technique, 2023–2031

Table 02: Global Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Brain Cancer Type, 2023–2031

Table 03: Global Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2023–2031

Table 04: Global Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Region, 2023–2031

Table 05: North America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Technique, 2023–2031

Table 06: North America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Brain Cancer Type, 2023–2031

Table 07: North America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2023–2031

Table 08: North America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2023–2031

Table 09: Europe Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Technique, 2023–2031

Table 10: Europe Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Brain Cancer Type, 2023–2031

Table 11: Europe Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2023–2031

Table 12: Europe Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

Table 13: Asia Pacific Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Technique, 2023–2031

Table 14: Asia Pacific Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Brain Cancer Type, 2023–2031

Table 15: Asia Pacific Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2023–2031

Table 16: Asia Pacific Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

Table 17: Latin America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Technique, 2023–2031

Table 18: Latin America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Brain Cancer Type, 2023–2031

Table 19: Latin America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2023–2031

Table 20: Latin America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

Table 21: Middle East & Africa Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Technique, 2023–2031

Table 22: Middle East & Africa Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Brain Cancer Type, 2023–2031

Table 23: Middle East & Africa Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2023–2031

Table 24: Middle East & Africa Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

List of Figures

Figure 01: Global Brain Cancer Diagnostics Market Value (US$ Mn) Forecast 2023–2031

Figure 02: Global Brain Cancer Diagnostics Market Value Share, by Diagnostic Technique 2023

Figure 03: Global Brain Cancer Diagnostics Market Value Share, by Brain Cancer Type 2023

Figure 04: Global Brain Cancer Diagnostics Market Value Share, by End-user 2023

Figure 05: Global Brain Cancer Diagnostics Market Value Share Analysis, by Diagnostic Technique 2023 and 2031

Figure 06: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Imaging Techniques 2023–2031

Figure 07: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Tissue Sampling/Biopsy 2023–2031

Figure 08: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Molecular Diagnostics 2023–2031

Figure 09: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Others 2023–2031

Figure 10: Global Brain Cancer Diagnostics Market Attractiveness Analysis, by Brain Cancer Type 2023–2031

Figure 11: Global Brain Cancer Diagnostics Market Value Share Analysis, by Brain Cancer Type 2023 and 2031

Figure 12: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Gliomas 2023–2031

Figure 13: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Meningiomas 2023–2031

Figure 14: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Pituitary Tumors 2023–2031

Figure 15: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Others 2023–2031

Figure 16: Global Brain Cancer Diagnostics Market Attractiveness Analysis, by End-user 2023–2031

Figure 17: Global Brain Cancer Diagnostics Market Value Share Analysis, by End-user 2023 and 2031

Figure 18: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Hospitals 2023–2031

Figure 19: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Diagnostic Laboratories 2023–2031

Figure 20: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Cancer Hospitals/Centers 2017–2032

Figure 21: Global Brain Cancer Diagnostics Market Value Share Analysis, by Region 2023 and 2031

Figure 22: Global Brain Cancer Diagnostics Market Attractiveness Analysis, by Region 2023–2031

Figure 23: North America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast 2023–2031

Figure 24: North America Brain Cancer Diagnostics Market Value Share Analysis, by Country 2023 and 2031

Figure 25: North America Brain Cancer Diagnostics Market Attractiveness Analysis, by Country 2023–2031

Figure 26: North America Brain Cancer Diagnostics Market Value Share Analysis, by Diagnostic Technique 2023 and 2031

Figure 27: North America Brain Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Technique 2023–2031

Figure 28: North America Brain Cancer Diagnostics Market Value Share Analysis, by Brain Cancer Type 2023 and 2031

Figure 29: North America Brain Cancer Diagnostics Market Attractiveness Analysis, by Brain Cancer Type 2023–2031

Figure 30: North America Brain Cancer Diagnostics Market Value Share Analysis, by End-user 2023 and 2031

Figure 31: North America Brain Cancer Diagnostics Market Attractiveness Analysis, by End-user 2023–2031

Figure 32: Europe Brain Cancer Diagnostics Market Value (US$ Mn) Forecast 2023–2031

Figure 33: Europe Brain Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

Figure 34: Europe Brain Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 35: Europe Brain Cancer Diagnostics Market Value Share Analysis, by Diagnostic Technique 2023 and 2031

Figure 36: Europe Brain Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Technique 2023–2031

Figure 37: Europe Brain Cancer Diagnostics Market Value Share Analysis, by Brain Cancer Type 2023 and 2031

Figure 38: Europe Brain Cancer Diagnostics Market Attractiveness Analysis, by Brain Cancer Type 2023–2031

Figure 39: Europe Brain Cancer Diagnostics Market Value Share Analysis, by End-user 2023 and 2031

Figure 40: Europe Brain Cancer Diagnostics Market Attractiveness Analysis, by End-user 2023–2031

Figure 41: Asia Pacific Brain Cancer Diagnostics Market Value (US$ Mn) Forecast 2023–2031

Figure 42: Asia Pacific Brain Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

Figure 43: Asia Pacific Brain Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 44: Asia Pacific Brain Cancer Diagnostics Market Value Share Analysis, by Diagnostic Technique 2023 and 2031

Figure 45: Asia Pacific Brain Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Technique 2023–2031

Figure 46: Asia Pacific Brain Cancer Diagnostics Market Value Share Analysis, by Brain Cancer Type 2023 and 2031

Figure 47: Asia Pacific Brain Cancer Diagnostics Market Attractiveness Analysis, by Brain Cancer Type 2023–2031

Figure 48: Asia Pacific Brain Cancer Diagnostics Market Value Share Analysis, by End-user 2023 and 2031

Figure 49: Asia Pacific Brain Cancer Diagnostics Market Attractiveness Analysis, by End-user 2023–2031

Figure 50: Latin America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast 2023–2031

Figure 51: Latin America Brain Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

Figure 52: Latin America Brain Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 53: Latin America Brain Cancer Diagnostics Market Value Share Analysis, by Diagnostic Technique 2023 and 2031

Figure 54: Latin America Brain Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Technique 2023–2031

Figure 55: Latin America Brain Cancer Diagnostics Market Value Share Analysis, by Brain Cancer Type 2023 and 2031

Figure 56: Latin America Brain Cancer Diagnostics Market Attractiveness Analysis, by Brain Cancer Type 2023–2031

Figure 57: Latin America Brain Cancer Diagnostics Market Value Share Analysis, by End-user 2023 and 2031

Figure 58: Latin America Brain Cancer Diagnostics Market Attractiveness Analysis, by End-user 2023–2031

Figure 59: Middle East & Africa Brain Cancer Diagnostics Market Value (US$ Mn) 2023–2031

Figure 60: Middle East & Africa Brain Cancer Diagnostics Market Value Share Analysis, by Country 2023 and 2031

Figure 61: Middle East & Africa Brain Cancer Diagnostics Market Attractiveness , by Country 2023–2031

Figure 62: Middle East & Africa Brain Cancer Diagnostics Market Value Share Analysis, by Diagnostic Technique 2023 and 2031

Figure 63: Middle East & Africa Brain Cancer Diagnostics Market Attractiveness , by Diagnostic Technique 2023–2031

Figure 64: Middle East & Africa Brain Cancer Diagnostics Market Value Share Analysis, by Brain Cancer Type 2023 and 2031

Figure 65: Middle East & Africa Brain Cancer Diagnostics Market Attractiveness , by Brain Cancer Type 2023–2031

Figure 66: Middle East & Africa Brain Cancer Diagnostics Market Value Share Analysis, by End-user 2023 and 2031

Figure 67: Middle East & Africa Brain Cancer Diagnostics Market Attractiveness, by End-user 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved